TW200306314A - Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation - Google Patents

Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation Download PDF

Info

Publication number
TW200306314A
TW200306314A TW092107354A TW92107354A TW200306314A TW 200306314 A TW200306314 A TW 200306314A TW 092107354 A TW092107354 A TW 092107354A TW 92107354 A TW92107354 A TW 92107354A TW 200306314 A TW200306314 A TW 200306314A
Authority
TW
Taiwan
Prior art keywords
glycine
liquid preparation
patent application
scope
group
Prior art date
Application number
TW092107354A
Other languages
English (en)
Chinese (zh)
Inventor
Takahiro Ito
Shinji Narisawa
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of TW200306314A publication Critical patent/TW200306314A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
TW092107354A 2002-04-16 2003-04-01 Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation TW200306314A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16

Publications (1)

Publication Number Publication Date
TW200306314A true TW200306314A (en) 2003-11-16

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092107354A TW200306314A (en) 2002-04-16 2003-04-01 Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation

Country Status (21)

Country Link
US (1) US20050215485A1 (https=)
EP (1) EP1501549A2 (https=)
JP (1) JP3927954B2 (https=)
KR (1) KR100700963B1 (https=)
CN (1) CN100544769C (https=)
AR (1) AR039272A1 (https=)
AU (1) AU2003223120B2 (https=)
BR (1) BR0309283A (https=)
CA (1) CA2480425A1 (https=)
HR (1) HRP20040894A2 (https=)
ME (1) MEP31308A (https=)
MX (1) MXPA04010178A (https=)
MY (1) MY136696A (https=)
NO (1) NO20044964L (https=)
PL (1) PL371677A1 (https=)
RS (1) RS91204A (https=)
RU (1) RU2315623C2 (https=)
TW (1) TW200306314A (https=)
UA (1) UA77295C2 (https=)
WO (1) WO2003086471A2 (https=)
ZA (1) ZA200408008B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005024923D1 (de) * 2004-02-13 2011-01-05 Yakult Honsha Kk Wässrige lösung mit einem camptothecin
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
JP5983608B2 (ja) * 2011-07-15 2016-09-06 コニカミノルタ株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
RU2717690C2 (ru) 2014-12-26 2020-03-25 Ниппон Каяку Кабусики Каися Фармацевтический состав полимерного производного, содержащего камптотецин
KR20180039628A (ko) 2015-09-03 2018-04-18 니폰 가야꾸 가부시끼가이샤 캄프토테신류 고분자 유도체를 함유하는 의약 조성물
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
RU2018129760A (ru) 2016-03-01 2020-04-01 Ниппон Каяку Кабусики Кайся Фармацевтический препарат, содержащий полимерное производное на основе камптотецина
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
KR20240105503A (ko) * 2021-11-26 2024-07-05 아스테라스 세이야쿠 가부시키가이샤 인도시아닌 화합물 함유 고형 의약 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
EP0540099B1 (en) * 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
AU2001271037A1 (en) * 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Also Published As

Publication number Publication date
AU2003223120A2 (en) 2003-10-27
RU2315623C2 (ru) 2008-01-27
RU2004133349A (ru) 2005-05-27
WO2003086471A3 (en) 2004-04-15
AR039272A1 (es) 2005-02-16
JP2005523329A (ja) 2005-08-04
JP3927954B2 (ja) 2007-06-13
MEP31308A (en) 2010-10-10
UA77295C2 (en) 2006-11-15
AU2003223120A1 (en) 2003-10-27
MY136696A (en) 2008-11-28
CA2480425A1 (en) 2003-10-23
NO20044964L (no) 2004-11-15
RS91204A (sr) 2006-12-15
CN100544769C (zh) 2009-09-30
US20050215485A1 (en) 2005-09-29
KR100700963B1 (ko) 2007-03-28
KR20050000516A (ko) 2005-01-05
MXPA04010178A (es) 2005-06-08
PL371677A1 (en) 2005-06-27
BR0309283A (pt) 2005-02-15
EP1501549A2 (en) 2005-02-02
CN1646172A (zh) 2005-07-27
ZA200408008B (en) 2005-06-13
HRP20040894A2 (en) 2005-10-31
AU2003223120B2 (en) 2006-10-05
WO2003086471A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
KR101502533B1 (ko) 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
TW200306314A (en) Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
PL205982B1 (pl) Liofilizowany preparat zawierający przeciwciała przeciw receptorowi EGF oraz sposób jego otrzymywania
CN101444510A (zh) 含有伏立康唑的药物制剂及其制备方法
JP2006137678A (ja) インターロイキン−2組成物
JP2003063965A (ja) 注射用シロスタゾール水性製剤
CN112516090B (zh) 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
JP2011157393A (ja) 組換え炭水化物結合ポリペプチドの安定型凍結乾燥生薬製剤
JP5052750B2 (ja) オリゴペプチドとエーテル化シクロデキストリンを含む液体製剤
JPS62164631A (ja) インタ−ロイキン−2組成物
JP4142149B2 (ja) バンコマイシンの凍結乾燥製剤
EP4628103A1 (en) Anti-her3 antibody-drug conjugate composition and pharmaceutical use thereof
WO2008023807A1 (fr) Composition pharmaceutique stabilisée
JPH06505755A (ja) 重合体誘導体結合アンスラサイクリン配糖体を含有する医薬組成物及びその製造方法
CN102784382B (zh) 一种阿加曲班药物组合物及其制备方法和应用
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
CN113616620B (zh) 安罗替尼白蛋白纳米颗粒及其制备方法和用途、及包含其的制剂
CN100428937C (zh) 左西孟旦冷冻干燥组合物
WO2025218800A1 (zh) 咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途
JPS6133127A (ja) 医薬活性化合物の包接化方法